Jubilation In US Over Covid-19 Vaccine

<p>Jubilation in US for the welcome addition of vaccines for emergency use<br &sol;>&NewLine;<strong><a href&equals;"https&colon;&sol;&sol;openlife&period;ng&sol;">OpenLife Nigeria<&sol;a> <&sol;strong>reports that there is <strong>jubilation<&sol;strong> in US following analysis released Wednesday by the US Food and Drug Administration which confirmed that Johnson &amp&semi; Johnson Covid-19 vaccine has met the requirements for emergency use authorization&period;<br &sol;>&NewLine;The efficacy of the Johnson &amp&semi; Johnson vaccine against moderate to severe&sol;critical Covid-19 across all geographic areas was 66&period;9&percnt; at least 14 days after the single dose vaccination and 66&period;1&percnt; at least 28 days after vaccination&comma; a new analysis meant to brief the FDA&&num;8217&semi;s Vaccines and Related Biological Products Advisory Committee said&period;<br &sol;>&NewLine;&&num;8220&semi;There were no specific safety concerns identified in subgroup analyses by age&comma; race&comma; ethnicity&comma; medical comorbidities&comma; or prior SARS-CoV-2 infection&comma;&&num;8221&semi; the analysis said&period;<br &sol;>&NewLine;In a briefing document&comma; the FDA said that it has reviewed the data for the vaccine and has determined that it is &&num;8220&semi;consistent with the recommendations set forth in FDA&&num;8217&semi;s guidance Emergency Use Authorization for Vaccines to Prevent COVID-19&period;&&num;8221&semi;<br &sol;>&NewLine;An independent group of FDA advisers&comma; the Vaccines and related Biological Products Advisory Committee&comma; will consider the documents and make a recommendation about whether the Covid-19 vaccination should be authorized&period; The committee meets on Friday&period;<&sol;p>&NewLine;